Athenex Valuation
Is 2MT0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2MT0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2MT0's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2MT0's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2MT0?
Key metric: As 2MT0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 2MT0's PS Ratio? | |
|---|---|
| PS Ratio | 0.1x |
| Sales | US$102.82m |
| Market Cap | US$9.88m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.9x |
| Enterprise Value/EBITDA | -1.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 2MT0's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.1x | ||
CNW co.don | 0.7x | n/a | €6.5m |
MDG1 Medigene | 3x | 16.1% | €22.5m |
BPXA Bellicum Pharmaceuticals | 0.5x | n/a | €772.4k |
HPHA Heidelberg Pharma | 12x | 16.6% | €102.1m |
2MT0 Athenex | 0.1x | -23.9% | €9.9m |
Price-To-Sales vs Peers: 2MT0 is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (14.6x).
Price to Sales Ratio vs Industry
How does 2MT0's PS Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Sales vs Industry: 2MT0 is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Biotechs industry average (8.1x).
Price to Sales Ratio vs Fair Ratio
What is 2MT0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.1x |
| Fair PS Ratio | 0.9x |
Price-To-Sales vs Fair Ratio: 2MT0 is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Aspen Pharmacare Holdings
R74.3b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R9.00
7D
0.6%
1Y
5.3%
Pharming Group
€492.8m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.71
7D
0.4%
1Y
-33.2%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.45
7D
1.1%
1Y
2.9%